Loading
Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.
Alexander Eggermont is Chief Scientific Officer of the Princess Máxima Center and Professor at Utrecht, and a former President of the EORTC and Director General of Gustave Roussy. A surgical oncologist by training, he specialises in melanoma and adjuvant immunotherapy. He led the EORTC trials that tested adjuvant checkpoint blockade in stage III melanoma: EORTC 18071 of adjuvant ipilimumab and KEYNOTE-054 of adjuvant pembrolizumab, the latter reported in the New England Journal of Medicine as a placebo-controlled trial of pembrolizumab after resection. His work helped establish immunotherapy after surgery in melanoma, and his publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054) | NEJM | 2018 |
Shares Gustave Roussy, Ipilimumab, Melanoma, Pembrolizumab.
Shares Stage III melanoma (after surgery), Ipilimumab, Melanoma, Pembrolizumab.
Shares Ipilimumab, Melanoma, Pembrolizumab.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab.
Shares Stage III melanoma (after surgery), Ipilimumab, Melanoma, Pembrolizumab.